Innovita Biological Technology Co. Ltd. A

SHG:688253 China Biotechnology
Market Cap
$729.43 Million
CN¥5.35 Billion CNY
Market Cap Rank
#12033 Global
#2924 in China
Share Price
CN¥39.07
Change (1 day)
+2.60%
52-Week Range
CN¥29.02 - CN¥39.07
All Time High
CN¥48.28
About

Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.

Innovita Biological Technology Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 70.49%

Innovita Biological Technology Co. Ltd. A (688253) has an Asset Resilience Ratio of 70.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥1.52 Billion
Cash + Short-term Investments
Total Assets
CN¥2.16 Billion
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Innovita Biological Technology Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Innovita Biological Technology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.52 Billion 70.49%
Total Liquid Assets CN¥1.52 Billion 70.49%

Asset Resilience Insights

  • Very High Liquidity: Innovita Biological Technology Co. Ltd. A maintains exceptional liquid asset reserves at 70.49% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Innovita Biological Technology Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Innovita Biological Technology Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Innovita Biological Technology Co. Ltd. A (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Innovita Biological Technology Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 71.61% CN¥1.58 Billion CN¥2.21 Billion -2.49pp
2023-12-31 74.10% CN¥1.53 Billion CN¥2.07 Billion +16.72pp
2022-12-31 57.38% CN¥1.11 Billion CN¥1.94 Billion +46.44pp
2021-12-31 10.93% CN¥87.25 Million CN¥797.87 Million -3.67pp
2020-12-31 14.61% CN¥114.26 Million CN¥782.09 Million --
pp = percentage points